<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1046">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05269394</url>
  </required_header>
  <id_info>
    <org_study_id>DIAN-TU-001 (E2814)</org_study_id>
    <secondary_id>The Alzheimer's Association</secondary_id>
    <secondary_id>U01AG042791</secondary_id>
    <secondary_id>2013-000307-17</secondary_id>
    <secondary_id>R01AG046179</secondary_id>
    <secondary_id>REec-2014-0817</secondary_id>
    <secondary_id>The Alzheimer's Association</secondary_id>
    <secondary_id>GHR Foundation</secondary_id>
    <secondary_id>Alzheimer's Association</secondary_id>
    <secondary_id>The Alzheimer's Association</secondary_id>
    <secondary_id>R56AG053267</secondary_id>
    <secondary_id>U01AG059798</secondary_id>
    <secondary_id>R01AG053267</secondary_id>
    <secondary_id>R01AG068319</secondary_id>
    <secondary_id>The Alzheimer's Association</secondary_id>
    <secondary_id>The Alzheimer's Association</secondary_id>
    <nct_id>NCT05269394</nct_id>
  </id_info>
  <brief_title>Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)</brief_title>
  <acronym>DIAN-TU</acronym>
  <official_title>A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Accelerating Medicines Partnership (AMP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of&#xD;
      investigational products in participants with an Alzheimer's disease-causing mutation by&#xD;
      determining if treatment with the study drug improves disease-related biomarkers and slows&#xD;
      the rate of progression of cognitive or clinical impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD) is characterized pathologically by the presence of accumulation of&#xD;
      amyloid plaques and tau-containing neurofibrillary tangles (NFTs) in the brain. Amyloid&#xD;
      plaques can be detectable within the brain some years before symptoms manifest whereas&#xD;
      tau-mediated toxicity has been hypothesized to appear later during the course of disease.&#xD;
      Physiologically, tau is predominantly a neuronal microtubule-associated protein that plays a&#xD;
      fundamental role in the stabilization of microtubules. Under pathological conditions however,&#xD;
      short motifs in the microtubule binding region (MTBR) domains of tau adopt a beta-sheet&#xD;
      conformation, inducing self-assembly with other tau molecules that lead to the formation of&#xD;
      insoluble aggregates. Insoluble tau is also a feature of a number of different&#xD;
      neurodegenerative diseases collectively termed tauopathies. The accumulation of insoluble&#xD;
      deposits has been suggested to result in altered distribution and function of organelles to&#xD;
      adversely affect neuronal cell function as well as causing synapse loss, ultimately leading&#xD;
      to cell death. In AD, evidence also suggests a direct correlation between the number of NFTs&#xD;
      found in the brain at postmortem and the degree of dementia observed in subjects with AD at&#xD;
      the time of death.&#xD;
&#xD;
      The microtubule-associated protein tau (MAPT) gene is located on chromosome 17 of the human&#xD;
      genome. Through alternative splicing, 6 possible tau protein isoforms are expressed from this&#xD;
      gene in the adult brain. A number of studies have suggested that pathological forms of tau&#xD;
      protein transmit from neuron to neuron in human brain to cause disease, including AD. It has&#xD;
      also been reported that tau can form seeds, which when applied extracellularly, can cause the&#xD;
      initiation and propagation of intracellular tau aggregation. To form tau seeds, the MTBR of&#xD;
      the protein is required. Furthermore, the tau MTBR is important in initiating the tau&#xD;
      aggregation process and forming the core of fibrils pathologically associated with disease.&#xD;
      Together, these observations suggest that therapeutic intervention with an antibody that&#xD;
      binds to the MTBR region of tau in the brain, thereby disrupting tau aggregation may prevent&#xD;
      initiation or slow down the neurodegeneration in AD or other tauopathies.&#xD;
&#xD;
      Upcoming Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trials are designed to&#xD;
      investigate therapies targeting tau in combination with amyloid as pre-specified in the&#xD;
      approved and NIH-funded NexGen Prevention Trial grants. As with other amyloid lowering drug&#xD;
      trials, clinical benefit was not definitively demonstrated in the symptomatic population&#xD;
      after tau pathology has been established. Determining the role of tau in disease biology and&#xD;
      progression is critically important. Based on beneficial effects on amyloid, tau, and&#xD;
      neurodegeneration markers associated with amyloid removal in the gantenerumab trial arm in&#xD;
      DIAN-TU, the DIAN-TU will now implement amyloid removal treatment in mutation carriers and&#xD;
      add placebo- controlled tau treatment arms. The platform trial design is exceptionally&#xD;
      well-suited for the investigation of treatments used in combination because of ongoing&#xD;
      multiple arms in a single trial and operational platform.&#xD;
&#xD;
      The current DIAN-TU amyloid removal drug arm has been extended to open-label extension (OLE)&#xD;
      periods for prior participants. All enrolled participants who opted-in for OLE were unblinded&#xD;
      to genetic status and offered open-label gantenerumab treatment. New treatment- naive&#xD;
      mutation positive participants will be started on amyloid removal treatment with genetic&#xD;
      counseling and testing. Therefore, all participants will be required to be positive for a&#xD;
      dominantly inherited Alzheimer's disease (DIAD) mutation and will receive open-label&#xD;
      treatment with lecanemab, an investigational amyloid removal drug, in combination with E2814,&#xD;
      an anti-tau drug or placebo. Mutation non-carriers will not be enrolled. Specifically, all&#xD;
      E2814 blinded drug arm participants will be treated with the lecanemab and randomized to&#xD;
      either active E2814 tau therapy, or placebo.&#xD;
&#xD;
      The goal of the study is to investigate potential benefits of anti-tau therapy while&#xD;
      anti-amyloid treatment is given as a background therapy. Furthermore, from ethical and&#xD;
      participant recruitment perspectives, launching drug trials using amyloid and tau targeting&#xD;
      therapies in combination may be essential, as participants and their families have expressed&#xD;
      the need to have a drug that changes amyloid disease pathology in addition to being&#xD;
      randomized to an investigational anti-tau drug (E2814) with uncertain benefit.&#xD;
&#xD;
      This record represents an analysis study portion of the Master Protocol Research Program&#xD;
      (MPRP) under NCT01760005&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2021</start_date>
  <completion_date type="Anticipated">October 2027</completion_date>
  <primary_completion_date type="Anticipated">July 2027</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interventional</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point is the change from Week 24 to Week 104 and Week 208 in tau PET in the Symptomatic Population (Cohort 1).</measure>
    <time_frame>Weeks 24, 104, and 208</time_frame>
    <description>To determine whether E2814 is superior to placebo, when each is concurrently administered with lecanemab, in the change from Week 24 to Week 104 (interim analysis) and Week 208 (final analysis) in tau spread as measured by tau PET in the symptomatic population (Cohort 1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Population (Cohort 1): Key Secondary: Change from Week 24 to Week 208 in Clinical Dementia Scale - Sum of Boxes (CDR-SB).</measure>
    <time_frame>Weeks 24, 52, 104, 156 and 208</time_frame>
    <description>To determine whether E2814 is superior to placebo, when each is concurrently administered with lecanemab, in change from Week 24 to Week 208 in CDR-SB&#xD;
Scores range from 0-18 with lower scores showing better outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic Population (Cohort 2): Key Secondary: Change from Week 0 to Week 104 and Week 208 in CSF ptau217/total tau</measure>
    <time_frame>Weeks 0, 104 and 208</time_frame>
    <description>To determine whether E2814 is superior to placebo, when each is administered alone and then concurrently with lecanemab, in change from Week 0 to Week 104 (interim analysis) and Week 208 (final analysis) in cerebrospinal fluid (CSF) phosphorylated tau (ptau217)/total tau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Population (Cohort 1): Change from Week 24 to Week 104 and Week 208 in the cognitive composite score</measure>
    <time_frame>Weeks 24, 52, 76, 104, 128, 156, 180 and 208</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Population (Cohort 1): Change from Week 0 to Week 24 in amyloid PET</measure>
    <time_frame>Week 0 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic Population (Cohort 2): Change from Week 0 to Week 52 in CSF ptau217/total tau</measure>
    <time_frame>Week 0 to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic population (Cohort 1): Change from Week 24 to Week 104 and Week 208 in CSF neurofilament light chain (NfL)</measure>
    <time_frame>Weeks 24, 104 and 208</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic Population (Cohort 2): Change from Week 52 to Week 104 and Week 208 in CSF neurofilament light chain (NfL)</measure>
    <time_frame>Weeks 52, 104 and 208</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Alzheimers Disease</condition>
  <condition>Dementia</condition>
  <condition>Alzheimers Disease, Familial</condition>
  <arm_group>
    <arm_group_label>E2814 plus lecanemab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symptomatic Population (Cohort 1)&#xD;
At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.&#xD;
At Week 24, participants randomized to E2814 will receive intravenously in a blinded fashion for the remainder of their treatment period.&#xD;
Asymptomatic Population (Cohort 2)&#xD;
At Week 0, participants randomized to E2814 will receive intravenously in a blinded fashion for the full treatment period.&#xD;
At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo (E2814) plus lecanemab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Symptomatic Population (Cohort 1)&#xD;
At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.&#xD;
At Week 24, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the remainder of their treatment period.&#xD;
Asymptomatic Population (Cohort 2)&#xD;
At Week 0, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the full treatment period.&#xD;
At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2814</intervention_name>
    <description>Administered intravenously in a blinded fashion</description>
    <arm_group_label>E2814 plus lecanemab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lecanemab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>E2814 plus lecanemab</arm_group_label>
    <arm_group_label>Matching placebo (E2814) plus lecanemab</arm_group_label>
    <other_name>BAN2401</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo (E2814)</intervention_name>
    <description>Placebo administered intravenously in a blinded fashion.</description>
    <arm_group_label>Matching placebo (E2814) plus lecanemab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Between 18-80 years of age&#xD;
&#xD;
          -  Individuals who know they have an Alzheimer's disease-causing mutation.&#xD;
&#xD;
          -  Are within -10 to + 10 years of the predicted or actual age of cognitive symptom&#xD;
             onset.&#xD;
&#xD;
          -  Cognitively normal or with mild cognitive impairment or mild dementia, Clinical&#xD;
             Dementia Rating (CDR) of 0-1 (inclusive)&#xD;
&#xD;
          -  Fluency in DIAN-TU trial approved language and evidence of adequate premorbid&#xD;
             intellectual functioning&#xD;
&#xD;
          -  Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron&#xD;
             Emission Tomography (PET), and complete all study related testing and evaluations.&#xD;
&#xD;
          -  For women of childbearing potential, if partner is not sterilized, participant must&#xD;
             agree to use effective contraceptive measures (hormonal contraception, intra-uterine&#xD;
             device, sexual abstinence, barrier method with spermicide).&#xD;
&#xD;
          -  Adequate visual and auditory abilities to perform all aspects of the cognitive and&#xD;
             functional assessments.&#xD;
&#xD;
          -  Has a Study Partner who in the investigator's judgment is able to provide accurate&#xD;
             information as to the subject's cognitive and functional abilities, who agrees to&#xD;
             provide information at the study visits which require informant input for scale&#xD;
             completion.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Significant neurologic disease (other than AD) or psychiatric disease that may&#xD;
             currently or during the course of the study affect cognition or participant's ability&#xD;
             to complete the study.&#xD;
&#xD;
          -  At high risk for suicide, e.g., significant suicidal ideation or attempt within last&#xD;
             12 months. Current stable mild depression or current use of antidepressant medications&#xD;
             is not exclusionary.&#xD;
&#xD;
          -  History or presence of brain MRI scans indicative of any other significant abnormality&#xD;
&#xD;
          -  Substance or alcohol use disorder currently or within the past 1 year&#xD;
&#xD;
          -  Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or&#xD;
             foreign metal objects in the eyes, skin or body which would preclude MRI scan.&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular disease, hepatic/renal&#xD;
             disorders, infectious disease or immune disorder, or metabolic/endocrine disorders&#xD;
&#xD;
          -  Anticoagulants except low dose (≤ 325 mg) aspirin.&#xD;
&#xD;
          -  Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the&#xD;
             past six months.&#xD;
&#xD;
          -  History of cancer within the last 5 years, except basal cell carcinoma, non-squamous&#xD;
             skin carcinoma, prostate cancer or carcinoma in situ with no significant progression&#xD;
             over the past 2 years.&#xD;
&#xD;
          -  Positive urine or serum pregnancy test or plans or desires to become pregnant during&#xD;
             the course of the trial.&#xD;
&#xD;
          -  Subjects unable to complete all study related testing, including implanted metal that&#xD;
             cannot be removed for MRI scanning, required anticoagulation and pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall J Bateman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Ziegemeier, MA</last_name>
    <phone>844-DIANEXR (342-6397)</phone>
    <email>dianexr@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Petranek</last_name>
    <phone>844-DIANEXR (342-6397)</phone>
    <email>dianexr@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama in Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erik Roberson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Hospital</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Barbara Snider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sarah Berman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ghulam Surti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerwin Research Center,</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Neurologicas Raul Carrea, FLENI</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <zip>C1428AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research Australia</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mental Health Research Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The McCuster Foundation of Alzheimer's Disease Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da USP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UBC Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill Center for Studies in Aging</name>
      <address>
        <city>Verdun</city>
        <state>Quebec</state>
        <zip>H4H 1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Hôpital de l' Enfant Jésus</name>
      <address>
        <city>Québec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert LaForce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grupo de Neurociencias Sede de la Universidad de Antioquia</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro - CHU Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris cedex 13</city>
        <state>Paris</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron cedex</city>
        <state>Rhone</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tubingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cristoph Laske, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU-Campus Grosshadern</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Johannes Levin, M.D,</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro San Giovanni di Dio Fatebenefratelli</name>
      <address>
        <city>Brescia</city>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giovanni Frisoni, M.D,</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sandro Sorbi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital</name>
      <address>
        <city>Niigata-shi</city>
        <state>Niigata-Ken</state>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Takeshi Ikeuchi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital Clinical Research Center of Dementia</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka-Fu</state>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hiroyuki Shimada, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tokyo Hospital</name>
      <address>
        <city>Bunkyō-Ku</city>
        <state>Tokyo-To</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ryoko Ihara, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14269</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brain Research Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 GM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico, School of Medicine</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ivonne Jimenez-Velazquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>WC1B 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dianexr.org/</url>
    <description>Expanded registry</description>
  </link>
  <reference>
    <citation>Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb;12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0.</citation>
    <PMID>23332364</PMID>
  </reference>
  <reference>
    <citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, Scheres SHW. Cryo-EM structures of tau filaments from Alzheimer's disease. Nature. 2017 Jul 13;547(7662):185-190. doi: 10.1038/nature23002. Epub 2017 Jul 5.</citation>
    <PMID>28678775</PMID>
  </reference>
  <reference>
    <citation>Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R, Crowther RA, Ghetti B, Scheres SHW, Goedert M. Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature. 2018 Sep;561(7721):137-140. doi: 10.1038/s41586-018-0454-y. Epub 2018 Aug 29.</citation>
    <PMID>30158706</PMID>
  </reference>
  <reference>
    <citation>Kopeikina KJ, Hyman BT, Spires-Jones TL. Soluble forms of tau are toxic in Alzheimer's disease. Transl Neurosci. 2012 Sep;3(3):223-233.</citation>
    <PMID>23029602</PMID>
  </reference>
  <reference>
    <citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-59. Review.</citation>
    <PMID>1759558</PMID>
  </reference>
  <reference>
    <citation>Goedert M, Spillantini MG. Propagation of Tau aggregates. Mol Brain. 2017 May 30;10(1):18. doi: 10.1186/s13041-017-0298-7. Review.</citation>
    <PMID>28558799</PMID>
  </reference>
  <reference>
    <citation>Falcon B, Cavallini A, Angers R, Glover S, Murray TK, Barnham L, Jackson S, O'Neill MJ, Isaacs AM, Hutton ML, Szekeres PG, Goedert M, Bose S. Conformation determines the seeding potencies of native and recombinant Tau aggregates. J Biol Chem. 2015 Jan 9;290(2):1049-65. doi: 10.1074/jbc.M114.589309. Epub 2014 Nov 18.</citation>
    <PMID>25406315</PMID>
  </reference>
  <reference>
    <citation>Barghorn S, Zheng-Fischhöfer Q, Ackmann M, Biernat J, von Bergen M, Mandelkow EM, Mandelkow E. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry. 2000 Sep 26;39(38):11714-21.</citation>
    <PMID>10995239</PMID>
  </reference>
  <reference>
    <citation>von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5129-34.</citation>
    <PMID>10805776</PMID>
  </reference>
  <reference>
    <citation>von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, Mandelkow E. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem. 2001 Dec 21;276(51):48165-74. Epub 2001 Oct 17.</citation>
    <PMID>11606569</PMID>
  </reference>
  <reference>
    <citation>Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ; Dominantly Inherited Alzheimer Network-Trials Unit. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021 Jul;27(7):1187-1196. doi: 10.1038/s41591-021-01369-8. Epub 2021 Jun 21.</citation>
    <PMID>34155411</PMID>
  </reference>
  <reference>
    <citation>Sandusky-Beltran LA, Sigurdsson EM. Tau immunotherapies: Lessons learned, current status and future considerations. Neuropharmacology. 2020 Sep 15;175:108104. doi: 10.1016/j.neuropharm.2020.108104. Epub 2020 Apr 28. Review.</citation>
    <PMID>32360477</PMID>
  </reference>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>January 13, 2022</study_first_submitted>
  <study_first_submitted_qc>February 24, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2022</study_first_posted>
  <last_update_submitted>August 4, 2022</last_update_submitted>
  <last_update_submitted_qc>August 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Mutation</keyword>
  <keyword>Genetic Mutation</keyword>
  <keyword>Dominantly Inherited Alzheimer's Disease</keyword>
  <keyword>Dominantly Inherited Alzheimer Network</keyword>
  <keyword>Autosomal Dominant Alzheimer's Disease</keyword>
  <keyword>Early Onset Alzheimer's Disease</keyword>
  <keyword>DIAN</keyword>
  <keyword>DIAN-TU</keyword>
  <keyword>DIAN TU</keyword>
  <keyword>DIAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to DIAN-TU trial data will follow the DIAN-TU data access policy, which complies with the guidelines established by the Collaboration for Alzheimer's Prevention [CAP REF].</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

